Pall Will Seek To Aid FDA In U.S. Leukocyte Filtration Initiatives
This article was originally published in The Gray Sheet
Pall Corporation will aid FDA through broad-scale programs in implementing routine leukocyte filtration of the U.S. blood supply, the company says.
You may also be interested in...
Universal leukocyte reduction of all blood units used for transfusions in the U.S. would roughly double the market for the blood filters to about $420 mil., annually.
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.